Lung Cancer News

CHICAGO — Maura Dickler, MD, vice president of late-phase oncology development at Eli Lilly, spoke with HemOnc Today about key data presented at ASCO Annual Meeting.

DALLAS — U.S. coal miner mortality from progressive massive fibrosis, a lethal form of black lung disease, has made a significant resurgence in recent years; however, a cause has yet to be determined, according to researchers.

CHICAGO — Alexandre Lebeaut, MD, head of research and development at Ipsen Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and promising investigational agents in its pipeline.

CHICAGO — Anthony “Andy” Boral, MD, PhD, chief medical officer at Blueprint Medicines, spoke with HemOnc Today at ASCO Annual Meeting about key study results the company presented and the investigational agents in its pipeline.

CHICAGO — Raj Malik, MD, chief medical officer and senior vice president for research and development at G1 Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about study results the company presented and the investigational agents in the pipeline.

DALLAS — In an analysis of the National Lung Screening Trial, adults who reported smoking unfiltered cigarettes had a 30% higher risk for all-cause mortality and were nearly twice as likely to die of lung cancer.

CHICAGO — Clive Morris, MD, CEO of Inivata, spoke with HemOnc Today at ASCO Annual Meeting about the company’s efforts to develop new clinical applications for liquid biopsy and circulating tumor DNA analysis.

A new battle in the decades-long war between tobacco companies and health advocates recently began when the FDA permitted Philip Morris’ IQOS Tobacco Heating System to go on the U.S. market.

Raja M. Flores, MD, received New York University’s Distinguished Alumni Service Award, which recognizes his accomplishments and services to the institution as both a student and alumnus.

The FDA approved NovoTTF-100L, a tumor-treating fields delivery system, for use in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma.